{"id":"W3016538158","doi":"10.1016/s0140-6736(20)30262-2","title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":612,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"National Cancer Institute","keywords":"Obinutuzumab; Chlorambucil; Medicine; Chronic lymphocytic leukemia; Internal medicine; Gastroenterology; Oncology; Leukemia; Cyclophosphamide; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001695761,0.002056092,0.003242653,0.0004051804,0.0004446088,0.001428271,0.001118151,0.001972771,0.008416586],"category_scores_gemma":[0.00201857,0.0006276712,0.002939559,0.0005500289,0.001397827,0.001293319,0.0005306936,0.0040063,0.001457622],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001139563,"about_ca_system_score_gemma":0.001090934,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002157669,"about_ca_topic_score_gemma":0.00528164,"domain_scores_codex":[0.9993357,0.0003599277,0.00003034081,0.0001100998,0.00004285964,0.0001210166],"domain_scores_gemma":[0.9991571,0.0002871734,0.0001837997,0.00006817948,0.00004269274,0.0002611992],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9846032,0.001226,0.0002311926,0.0007495635,0.001212646,0.00003202928,0.00003865422,0.000224028,0.00103914,0.0001454511,0.000987619,0.009510538],"study_design_scores_gemma":[0.9854531,0.01276234,0.0005037701,0.00003478167,0.0003807324,0.00002009219,0.00001256124,0.000118669,0.00007088778,0.0001565748,0.0004786792,0.000007849858],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9574988,0.02450997,0.001217709,0.001991095,0.002249459,0.004388575,0.002508934,0.0002918709,0.005343586],"genre_scores_gemma":[0.9736319,0.008419069,0.001859803,0.002520138,0.0008841968,0.004070534,0.002024328,0.00005569729,0.006534236],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008416586,"threshold_uncertainty_score":0.02815628,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1071913197879008,"score_gpt":0.3732692195852925,"score_spread":0.2660778997973917,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}